Breast Cancer Coverage from Every Angle

Andrea De Censi, MD: What Does the Clinical Future Look Like for Low-Dose Tamoxifen in Noninvasive Breast Cancer?

Posted: Thursday, January 5, 2023

Andrea De Censi, MD, PhD, of Italy’s E.O. Ospedali Galliera, gives clinical context to his findings that low-dose tamoxifen (so-called babytam) given for 3 years still significantly prevents recurrences from noninvasive breast cancer after a median of 7 years from treatment cessation. Dr. De Censi discusses patient selection, the advantages of lower-dose tamoxifen, and the long-term outlook.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.